News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Celcuity Inc.
Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer
July 18, 2022
From
Celcuity Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
CELC
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
May 26, 2022
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates
May 16, 2022
From
Celcuity Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
CELC
Celcuity Inc. Announces $100 Million Private Placement
May 16, 2022
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call
May 09, 2022
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences
April 05, 2022
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates
March 23, 2022
From
Celcuity Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
CELC
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2021 Financial Results and Webcast/Conference Call
March 16, 2022
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity to Participate in the Cowen 42nd Annual Health Care Conference
March 02, 2022
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update
January 18, 2022
From
Celcuity Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
CELC
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symposium
December 10, 2021
From
Celcuity Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
CELC
Celcuity to Present at the 2021 San Antonio Breast Cancer Symposium
December 02, 2021
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process Development
November 29, 2021
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (palbociclib) for Planned Phase 3 Clinical Trial
November 15, 2021
From
Celcuity Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
CELC
Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences
November 09, 2021
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 08, 2021
From
Celcuity Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Product Safety
Tickers
CELC
Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference Call
October 29, 2021
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases
October 18, 2021
From
Celcuity Inc.
Via
Business Wire
Tickers
CELC
Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 09, 2021
From
Celcuity Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
CELC
Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference
August 05, 2021
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast
August 02, 2021
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity to Participate in the William Blair Biotech Focus Conference
July 08, 2021
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Announces Pricing of Follow-on Offering
June 28, 2021
From
Celcuity Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Tickers
CELC
Celcuity Announces Launch of Follow-on Offering
June 28, 2021
From
Celcuity Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Tickers
CELC
Celcuity Announces Appointment of Dr. Igor Gorbatchevsky as VP of Clinical Development and Jill Krause as VP of Clinical Operations
June 09, 2021
From
Celcuity Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
CELC
Celcuity Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 10, 2021
From
Celcuity Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
CELC
Celcuity Inc. Schedules Release of First Quarter 2021 Financial Results and Webcast
April 26, 2021
From
Celcuity Inc.
Via
AccessWire
Exposures
COVID-19
Tickers
CELC
Celcuity Presents Data at AACR Annual Meeting Assessing Gedatolisib, a pan-PI3K/mTOR Inhibitor, in HER2-negative Breast and Ovarian Cancer Patient Tumors with Hyperactive RAS Network Signaling
April 12, 2021
From
Celcuity Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
CELC
Celcuity Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus Ibrance® and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides Corporate Update
April 08, 2021
From
Celcuity Inc.
Via
Business Wire
Tickers
CELC
Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer
April 08, 2021
From
Celcuity Inc.
Via
Business Wire
Tickers
CELC
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.